Cancer BiomarkersAn Invitation to the Table-Reference-Cited by-同舟云学术

Cancer BiomarkersAn Invitation to the Table

Published:2006-05-26 Issue:5777 Volume:312 Page:1165-1168
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Dalton William S.¹²,Friend Stephen H.¹²

Affiliation:

1. H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33613, USA.

2. Merck Research Laboratories, West Point, PA 19846, USA.

Abstract

The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference24 articles.

1. American Cancer Society Cancer statistics 2005 at (www.cancer.org).

2. Use of genomic signatures in therapeutics development in oncology and other diseases

3. L. M. Hernandez Implications of Genomics for Public Health: Workshop Summary (Committee on Genomics and the Public's Health in the 21st Century Institute of Medicine National Academies Press Washington DC 2005); (www.nap.edu/catalog/11260.html).

4. Evaluating markers for the early detection of cancer: overview of study designs and methods

5. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum tumor marker and CT body composition scoring system predicts outcomes in colorectal cancer surgical patients;European Radiology;2024-06-24

2. A Proactive Intervention Study in Metabolic Syndrome High-Risk Populations Using Phenome-Based Actionable P4 Medicine Strategy;Phenomics;2024-04

3. Calnexin as a dual-role biomarker: antibody-based diagnosis and therapeutic targeting in lung cancer;BMB Reports;2024-02-15

4. The Role of Mannose-Binding Lectin and Inflammatory Markers in Establishing the Course and Prognosis of Community-Acquired Pneumonia in Children;Children;2023-10-27

5. Towards Data Driven RT Prescription: Integrating Genomics into RT Clinical Practice;Seminars in Radiation Oncology;2023-07